PD L1 News and Research

RSS

Targeting super-enhancer mechanisms offers new strategies for cancer therapy

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create "transcriptional addiction" in cancer.

13 Apr 2026

High affinity for immune receptors predicts antibody drug associated anaphylaxis risk

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory molecules.

8 Apr 2026

Lactate modification fuels drug resistance and immune escape in cancer

Published in Current Molecular Pharmacology, a comprehensive review led by Yong Xu and colleagues from Shanghai Pulmonary Hospital explores the emerging role of lactylation, a post-translational modification driven by lactate, in lung cancer progression and drug resistance.

7 Apr 2026

Study explores racial differences in gastric cancer immunotherapy outcomes

Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%.

26 Mar 2026

Healthy thymus gland linked to longer life and immune stability

The thymus is a small organ located in the upper chest that plays a central role in the immune system: it produces T cells - specialized immune cells that recognize and fight pathogens.

26 Mar 2026

Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

25 Mar 2026

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026

Protein targeted by cancer drugs may help the body fight influenza

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX).

18 Mar 2026

New insights highlight multifaceted roles of CD4+ T cells in tumor immunity

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell killing.

13 Mar 2026

Microbial ecosystems influence success of cancer checkpoint immunotherapy

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

9 Mar 2026

Distinct spatial tumor–immune ecosystems predict lung cancer treatment response

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

5 Mar 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

New strategy harnesses pre-existing antiviral immunity to boost anti-tumor responses

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy.

11 Feb 2026

Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

29 Jan 2026

Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and the 5-year survival for advanced/metastatic disease is <10%.

24 Jan 2026

Inhalable nanotherapy can activate the immune system against checkpoint-resistant melanoma

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the body's own cells.

5 Jan 2026

Study uncovers how aggressive breast cancer cells escape immune defenses

With a new study in the journal Science Bulletin, researchers at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University have discovered a new way that aggressive breast cancer cells escape the immune defenses.

1 Jan 2026

Engineered extracellular vesicles enable antigen-specific regulatory T cell induction

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of inducing antigen-specific regulatory T cells (Tregs), the immune cells that play a central role in suppressing excessive immune responses.

22 Dec 2025

Frog-derived bacteria offer dual-action anticancer effects and high safety

A research team of Prof. Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST) has discovered that the bacterium Ewingella americana, isolated from the intestines of Japanese tree frogs (Dryophytes japonicus), possesses remarkably potent anticancer activity. This groundbreaking research has been published in the international journal Gut Microbes.

16 Dec 2025

Scientists engineer AbLecs to overcome cancer's immune evasion tactics

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.

16 Dec 2025